The Efficacy of Human Papillomavirus Vaccination as an Adjuvant Therapy in Recurrent Respiratory Papillomatosis
The Laryngoscope · 2023
DOI: 10.1002/lary.30560 ↗Kurz gefasst
Metaanalyse in der Zeitschrift The Laryngoscope, 2023. Verfasst von Anusha Ponduri und 9 weiteren Autor:innen. Beteiligte Einrichtung: Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Papillomavirus Vaccines, Papillomavirus Infections, Respiratory Tract Infections. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Objective
To characterize the efficacy of human papillomavirus (HPV) vaccination as an adjuvant therapy in recurrent respiratory papillomatosis (RRP). Data Sources PubMed, Embase, Cochrane, Google Scholar, ClinicalTrials.gov , and Web of Science databases were queried for articles published before April 2021. Review Methods All retrieved studies ( n = 870) were independently analyzed by two reviewers according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA) statement using predefined inclusion and exclusion criteria. 13 studies met inclusion criteria. A random‐effects meta‐analysis was performed to study intersurgical interval (ISI) and number of surgical procedures per year before and after vaccination.
Results
The systematic review included 13 studies, comprising 243 patients. All studies utilized the Gardasil® quadrivalent vaccine, and one study (Yiu et al. 2019) utilized both the quadrivalent and Gardasil® 9‐valent vaccines. Our meta‐analysis included 62 patients with ISI data across 4 studies, and 111 patients with data on the number of surgical procedures per month across 7 studies. The mean number of surgical procedures decreased by 4.43 per year after vaccination (95% CI, −7.48 to −1.37). Mean ISI increased after vaccination, with a mean difference of 15.73 months (95% CI, 1.46–29.99). Two studies reported on HPV sero‐conversion, with HPV seropositivity of 100% prior to vaccination and 25.93% after vaccination.
Conclusion
The addition of HPV vaccination was associated with an increase in time between surgeries and reduction in the number of surgical procedures required. HPV vaccination may be a beneficial adjuvant treatment for RRP. Level of Evidence NA Laryngoscope , 133:2046–2054, 2023
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Albert Einstein College of Medicine, Bronx, New York, USA.
- Department of Otorhinolaryngology - Head and Neck Surgery, Montefiore Medical Center, Bronx, New York, United States.
- Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
- Department of Otorhinolaryngology/Head and Neck Surgery, Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands.
ORCID-Profile: Anusha Ponduri, Rachel Schwartz, Magdalena Chirilă, Frederik G Dikkers, Christina J Yang
Förderung
- NCATS NIH HHS
Zitieren
APA
Ponduri, A., Azmy, M. C., Axler, E., Lin, J., Schwartz, R., Chirilă, M., Dikkers, F. G., Yang, C. J., Mehta, V., & Gangar, M. (2023). The Efficacy of Human Papillomavirus Vaccination as an Adjuvant Therapy in Recurrent Respiratory Papillomatosis. The Laryngoscope. https://doi.org/10.1002/lary.30560
Vancouver
Ponduri A, Azmy MC, Axler E, Lin J, Schwartz R, Chirilă M, et al. The Efficacy of Human Papillomavirus Vaccination as an Adjuvant Therapy in Recurrent Respiratory Papillomatosis. The Laryngoscope. 2023. doi:10.1002/lary.30560
BibTeX
@article{Ponduri2023,
author = {Ponduri, Anusha and Azmy, Monica C and Axler, Eden and Lin, Juan and Schwartz, Rachel and Chirilă, Magdalena and Dikkers, Frederik G and Yang, Christina J and Mehta, Vikas and Gangar, Mona},
title = {The Efficacy of Human Papillomavirus Vaccination as an Adjuvant Therapy in Recurrent Respiratory Papillomatosis},
journal = {The Laryngoscope},
year = {2023},
doi = {10.1002/lary.30560}
}
EUVIMED